{"id":"us-licensed-humira","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2109615","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to TNF-alpha, Humira inhibits the inflammatory cascade, which is a key component of various autoimmune diseases. This results in reduced inflammation and alleviation of symptoms associated with conditions such as rheumatoid arthritis and psoriasis.","oneSentence":"Humira is a monoclonal antibody that targets and binds to tumor necrosis factor-alpha (TNF-alpha), preventing it from interacting with its cell surface receptor and thereby reducing inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:18.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid Arthritis"},{"name":"Psoriatic Arthritis"},{"name":"Plaque Psoriasis"},{"name":"Crohn's Disease"},{"name":"Ulcerative Colitis"},{"name":"Juvenile Idiopathic Arthritis"},{"name":"Ankylosing Spondylitis"}]},"trialDetails":[{"nctId":"NCT05108259","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects","status":"RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2022-03-30","conditions":"Healthy Volunteers","enrollment":324},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT03970824","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-05-31","conditions":"Healthy","enrollment":312},{"nctId":"NCT03014947","phase":"PHASE1","title":"MSB11022 in Healthy Subjects","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2014-05","conditions":"Healthy Subjects","enrollment":237},{"nctId":"NCT02744755","phase":"PHASE3","title":"Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2016-03-31","conditions":"Rheumatoid Arthritis","enrollment":353},{"nctId":"NCT02137226","phase":"PHASE3","title":"BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-01-26","conditions":"Arthritis, Rheumatoid","enrollment":645}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adalimumab"],"phase":"phase_3","status":"active","brandName":"US-licensed Humira","genericName":"US-licensed Humira","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"US-licensed Humira is a medication that inhibits Interleukin-6, a protein involved in inflammation. It is used to treat conditions such as rheumatoid arthritis, as indicated by clinical trials registered on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}